Steven Lommatzsch, MD
Pulmonary Disease · Denver, CONPI 1750309571
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Mannkind Corporation accounts for 65.1% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $4,650, more than ten times the $358 reported in 2019.
Across 44 payments — averaging $142.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mannkind Corporation$4K
- Insmed, Inc.$525
- GSK$437
- AbbVie$379
- Pharming Healthcare, Inc.$247
- Genentech USA, Inc.$196
- plus $399 from 7 others
Across 7 payments — averaging $4532.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$32K
What the payments were for
- Speaking & faculty fees$3,50056%
- Travel & lodging$5489%
- Food & beverage$2,17835%
- Education$310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mannkind Corporation | 3 | $4,073 |
| Insmed, Inc. | 5 | $525 |
| GSK | 10 | $437 |
| AbbVie(2 entities) | 10 | $379 |
| Pharming Healthcare, Inc. | 2 | $247 |
| Genentech USA, Inc. | 5 | $196 |
| AstraZeneca | 2 | $142 |
| Boehringer Ingelheim | 1 | $110 |
| Pulmonx Corporation | 1 | $78 |
| Sanofi | 2 | $28 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Gilead | 1 | $14 |
| Olympus America Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,257 in reported general payments places this provider in the 75th percentile of 248 pulmonary disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 124 | $3,449,878 |
| KalydecoIvacaftor | 14 | $348,145 |
| Dupixent PenDupilumab | 57 | $214,143 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 151 | $184,451 |
| CreonLipase/Protease/Amylase | 34 | $176,500 |
| ZemairaAlpha-1-Proteinase Inhibitor | 23 | $148,792 |
| Fasenra PenBenralizumab | 23 | $135,032 |
| ZenpepLipase/Protease/Amylase | 19 | $117,620 |
| Spiriva RespimatTiotropium Bromide | 112 | $93,796 |
| Spiriva HandihalerTiotropium Bromide | 57 | $50,984 |
| Advair HfaFluticasone Propion/Salmeterol | 95 | $49,789 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 38 | $47,435 |
| TezspireTezepelumab-Ekko | 11 | $46,142 |
| SymbicortBudesonide/Formoterol Fumarate | 124 | $45,552 |
| DuleraMometasone/Formoterol | 58 | $36,097 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $437 | $257,179294 claims |
| AbbVieCreon | $379 | $176,50034 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $142 | $139,129173 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $110 | $123,627171 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 248 pulmonary disease providers in Colorado.
Other pulmonary disease in Denver
- Michael WechslerDenver$2.7M
- Ronald BalkissoonDenver$1.2M
- Vamsi GunturDenver$310K
- Kevin BrownDenver$299K
- Rebecca KeithDenver$248K
- Marjorie GeorgeDenver$192K
- Everett SutherlandDenver$174K
- Charles DaleyDenver$166K
- Barry MakeDenver$162K
- Amy OlsonDenver$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.